JPMorgan to price capped return enhanced notes linked to pharma stocks

By Angela McDaniels

Tacoma, Wash., Feb. 5 - JPMorgan Chase & Co. plans to price 0% capped return enhanced notes due Feb. 25, 2015 linked to an equally weighted basket of stocks, according to an FWP filing with the Securities and Exchange Commission.

The basket includes the common stocks of Actavis, Inc., Endo Health Solutions Inc., Mylan Inc. and Valeant Pharmaceuticals International, Inc.

If the basket return is positive, the payout at maturity will be par plus 1.5 times the basket return, subject to a maximum return that is expected to be at least 25.575%. If the basket return is negative, investors will have 1-to-1 exposure to the decline.

The final basket level will be the average of the basket's closing levels on the five trading days ending Feb. 20, 2015.

J.P. Morgan Securities LLC is the agent.

The notes will price Feb. 7 and settle Feb. 12.

The Cusip number is 48126N3G0.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.